Bacterial vaginosis (BV), an infection affecting nearly one in three women, has long been known for its frustrating tendency to return even after treatment. However, a groundbreaking study from Australia has revealed that treating male partners alongside their female counterparts can significantly reduce the recurrence of BV. This discovery also challenges the long-held belief that BV is not sexually transmitted.

BV and Its Controversial Transmission Debate

The research, published in the New England Journal of Medicine, marks a significant step toward improving treatment outcomes for women. According to co-author Professor Catriona Bradshaw, a sexual health expert at Melbourne’s Alfred Health and a researcher at Monash University, this study provides the first major breakthrough in reducing BV recurrence by addressing reinfection through untreated male partners.

Professor Gilda Tachedjian of the Burnet Institute, who was not directly involved in the study but has collaborated with Professor Bradshaw, called it a "landmark" piece of research. The study confirms that BV recurrence is, at least in part, linked to bacterial transfer from male to female partners.

Understanding BV: Causes, Symptoms, and Risks

BV is characterized by an imbalance in the vaginal microbiome, leading to symptoms such as a watery discharge and a strong fishy odor, which can cause significant distress. While many women experience no severe complications, BV can increase susceptibility to sexually transmitted infections (STIs) and pose risks such as pelvic inflammatory disease, miscarriage, preterm birth, and low birth weight in infants.

Unlike STIs like gonorrhea and chlamydia, which stem from specific bacteria, BV results from a disruption in the natural microbial environment. It frequently develops after sexual contact with a new partner, and although some women can naturally clear the infection, others require antibiotics. Unfortunately, BV often returns within months of treatment.

Why Does BV Keep Coming Back?

There have been various theories about BV’s persistence. One possibility is that BV-causing bacteria create protective biofilms that shield them from antibiotics, allowing them to re-emerge later. Lifestyle factors such as douching or unprotected sex may also play a role, as semen can alter the vaginal microbiome, making it more hospitable to these bacteria.

Despite early resistance to the idea that BV could be transmitted through heterosexual intercourse, anecdotal and clinical evidence suggested otherwise. Women in monogamous relationships with a single male partner frequently experienced recurrent BV, while those who had never engaged in sexual activity remained unaffected.

Partner Treatment: A Game-Changer?

Previous studies from the 1980s attempted to treat BV by giving antibiotics to both women and their male partners. However, because these trials only used oral antibiotics, they were largely unsuccessful in preventing reinfection, leading researchers to dismiss the role of penile bacteria in BV transmission.

To address this, Professor Bradshaw’s team designed a new clinical trial, administering both oral and topical antibiotics to male partners while their female partners received standard BV treatment. The study initially aimed to recruit 350 couples but was halted after just 160 due to overwhelmingly positive results.

The findings were striking: 63% of women whose partners were untreated experienced BV recurrence within 12 weeks, compared to only 35% of those whose partners also received treatment.

Challenges and the Road Ahead

Despite these promising results, the treatment protocol is not yet ready for widespread clinical implementation. According to Dr. Clare Keogh of SHINE SA, further studies are needed before clinical guidelines can be updated. One potential challenge is ensuring that male partners adhere to the treatment regimen, as applying topical antibiotics twice daily can be cumbersome.

Recruiting men for the trial was difficult, and even among those who participated, one in seven admitted to not completing at least 70% of their prescribed treatment. Additionally, factors such as intrauterine devices (IUDs) and variations in vaginal microbiomes may also impact BV recurrence, even with partner treatment.

Looking to the Future

For BV treatment recommendations to evolve, additional studies must be conducted across diverse populations, including same-sex couples and individuals from different cultural backgrounds. As Professor Tachedjian noted, expanding the research could help inform new policies and treatment strategies.

Professor Bradshaw hopes that national BV treatment guidelines will eventually recognize partner treatment as a standard approach. However, she also believes that the term "bacterial vaginosis" itself may need rebranding, emphasizing that BV is a shared issue rather than solely a female concern.

As research continues, one thing is becoming clearer: treating BV effectively may require a shift in how we view its transmission and recurrence. Recognizing BV as a condition influenced by both partners could be the key to finally breaking the cycle of reinfection.

Preventing Unwanted Vaginal Infections 

Here at CondomSales we offer a wide array of disease preventing condoms.  Find your condom size here or contact us on 1300 426 636 for further information